Biotechnology · Norwood, Massachusetts, United States
$11.21
+3.46% (+$0.38)2026-08-25
Smart-Money SignalNeutral · 47/100— Insiders are net sellers over 90 days (-$239K, 5 sales vs 5 buys)
Net Income-$35.0M
EPS$-3.04
Market Cap$209.2M
Price Performance
Historical data including institutional events
Company Profile
Y
Yuval Cohen
CEO & Executive Director
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity.
Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity.
The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.
